Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers
Genetic subtyping more accurately reflects clinical behaviour than reliance on pathologic classification only
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
A Phase III Study of Spartalizumab in Combination with Dabrafenib and Trametinib Did Not Meet Primary Endpoint in BRAF V600–Mutated Metastatic Melanoma
Findings from the COMBI-I study
Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant OS Improvement in Patients with HER2-positive Metastatic Breast Cancer
Final overall survival analysis from the HER2CLIMB study
Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early Breast Cancer
Findings from the FinXX study
Impressive Responses to PD-1 Blockade in a Large Cohort of Children and Young Adults with Recurrent/Progressive Germline DNA Replication Repair-Deficient Cancers
Findings from the International Replication Repair Deficiency Consortium registry-based study
Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma
Findings from the GOG-0261 study
Pembrolizumab Demonstrates Robust and Durable Antitumour Activity in Patients with Previously Treated Advanced MSI-H/dMMR Endometrial Cancer
Efficacy and safety data in a larger number of patients and longer follow-up from KEYNOTE-158 study
Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer
Patients with cancer who develop breakthrough COVID-19 remain at risk of severe outcomes despite full vaccination
Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate Cancer with Combination Treatment Than with ADT Alone
Findings from a meta-analysis of two randomised controlled phase III studies of the STAMPEDE platform protocol
Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated Metastatic or Unresectable Melanoma
RELATIVITY-047 validates LAG-3 as the third immune checkpoint inhibition pathway of clinical benefit
EMA Recommends Extension of Indications for Tegafur
New indication concerns the treatment of patients with metastatic colorectal cancer for whom due to toxicity is not possible to continue treatment with another fluoropyrimidine
EMA Recommends Granting a Marketing Authorisation for Tepotinib
It is indicated for the treatment of adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping